EVO:NASDAQ
Evotec SE
US$ 1.86
arrow_downward
-2.11%(-0.040) Siku 1
4 Sep, 16:00:01 GMT -4 · USD
search
Alama zote
Siku 1
Siku 5
Mwezi 1
Miezi 6
YTD
Mwaka 1
Miaka 5
ISIZIDI
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya EVO...
Fungua
US$ 1.86
Juu
US$ 1.86
Chini
US$ 1.84
Mtaji wa soko
667.16M
Wastani wa kiasi cha mauzo
elfu 60.68
Kiasi cha mauzo ya hisa
elfu 121.91
Juu kwa wiki 52
US$ 4.27
Chini kwa wiki 52
US$ 1.80
EPS
-US$ 0.64
Beta
1.92
Hisa za wawekezaji
355.82M
Idadi ya wafanyakazi
elfu 4
Fungua
US$ 1.86
Juu
US$ 1.86
Chini
US$ 1.84
Mtaji wa soko
667.16M
Wastani wa kiasi cha mauzo
elfu 60.68
Kiasi cha mauzo ya hisa
elfu 121.91
Juu kwa wiki 52
US$ 4.27
Chini kwa wiki 52
US$ 1.80
EPS
-US$ 0.64
Beta
1.92
Hisa za wawekezaji
355.82M
Idadi ya wafanyakazi
elfu 4
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
AD HOC NEWS
·
saa 9 zilizopita
Evotec stock falls again as weak half-year figures and guidance weigh on sentiment
AD HOC NEWS
·
saa 18 zilizopita
Evotec stock holds near 52-week low as new T-cell alliance meets weak earnings
AD HOC NEWS
·
siku 1 iliyopita
Evotec's New T-Cell Alliance Raises the Stakes on a Stock Already Testing Its Floor
AD HOC NEWS
·
siku 1 iliyopita
Evotec stock gains on Plectonic deal as TecDAX name rebounds
Wasifu
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Kuhusu Evotec SE